Global Epidemiological Impact of PNPLA3 I148M on Liver Disease
- PMID: 39373119
- PMCID: PMC11815610
- DOI: 10.1111/liv.16123
Global Epidemiological Impact of PNPLA3 I148M on Liver Disease
Abstract
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has increased exponentially over the past three decades, in parallel with the global rise in obesity and type 2 diabetes. It is currently the most common cause of liver-related morbidity and mortality. Although obesity has been identified as a key factor in the increased prevalence of MASLD, individual differences in susceptibility are significantly influenced by genetic factors. PNPLA3 I148M (rs738409 C>G) is the variant with the greatest impact on the risk of developing progressive MASLD and likely other forms of steatotic liver disease. This variant is prevalent across the globe, with the risk allele (G) frequency exhibiting considerable variation. Here, we review the contribution of PNPLA3 I148M to global burden and regional differences in MASLD prevalence, focusing on recent evidence emerging from population-based sequencing studies and prevalence assessments. We calculated the population attributable fraction (PAF) as a means of quantifying the impact of the variant on MASLD. Furthermore, we employ quantitative trait locus (QTL) analysis to ascertain the associations between rs738409 and a range of phenotypic traits. This analysis suggests that these QTLs may underpin pleiotropic effects on extrahepatic traits. Finally, we outline potential avenues for further research and identify key areas for investigation in future studies.
Keywords: PNPLA3; HSD17B13; MASH; MASLD; genetics; rs6006460; rs738409.
© 2024 The Author(s). Liver International published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures


Similar articles
-
[Cardiometabolic and genetic factors in the progression of metabolic dysfunction-associated steatotic liver disease].Ter Arkh. 2025 Mar 26;97(2):149-156. doi: 10.26442/00403660.2025.02.203203. Ter Arkh. 2025. PMID: 40237751 Russian.
-
Type 2 diabetes and the minor allele of PNPLA3 consistently identify high-risk metabolic dysfunction associated steatotic liver disease.Diabetes Res Clin Pract. 2025 Jan;219:111960. doi: 10.1016/j.diabres.2024.111960. Epub 2024 Dec 13. Diabetes Res Clin Pract. 2025. PMID: 39675485
-
PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease.Liver Int. 2025 Mar;45(3):e16106. doi: 10.1111/liv.16106. Epub 2024 Nov 19. Liver Int. 2025. PMID: 39559944 Free PMC article. Review.
-
Relevance of PNPLA3, TM6SF2, HSD17B13, and GCKR Variants to MASLD Severity in an Egyptian Population.Genes (Basel). 2024 Apr 4;15(4):455. doi: 10.3390/genes15040455. Genes (Basel). 2024. PMID: 38674389 Free PMC article.
-
PNPLA3 variation and kidney disease.Liver Int. 2025 Mar;45(3):e16010. doi: 10.1111/liv.16010. Epub 2024 Jun 14. Liver Int. 2025. PMID: 38873992 Review.
Cited by
-
Statin use and liver-related prognosis among patients with MASLD.JHEP Rep. 2024 Dec 24;7(4):101313. doi: 10.1016/j.jhepr.2024.101313. eCollection 2025 Apr. JHEP Rep. 2024. PMID: 40124167 Free PMC article.
-
PNPLA3 Polymorphism Is Inversely Correlated with Aortic Stiffness in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Without Fibrosis.Int J Mol Sci. 2025 Apr 1;26(7):3256. doi: 10.3390/ijms26073256. Int J Mol Sci. 2025. PMID: 40244110 Free PMC article.
-
Fifteen Years of PNPLA3: Transforming Hepatology Through Human Genetics.Liver Int. 2025 Sep;45(9):e70240. doi: 10.1111/liv.70240. Liver Int. 2025. PMID: 40747912 Free PMC article. Review.
-
Lipid Accumulation and Insulin Resistance: Bridging Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease.Int J Mol Sci. 2025 Jul 20;26(14):6962. doi: 10.3390/ijms26146962. Int J Mol Sci. 2025. PMID: 40725208 Free PMC article. Review.
-
Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Narrative Review.Int J Mol Sci. 2025 May 28;26(11):5164. doi: 10.3390/ijms26115164. Int J Mol Sci. 2025. PMID: 40507973 Free PMC article. Review.
References
-
- Quek J., Chan K. E., Wong Z. Y., et al., “Global Prevalence of Non‐Alcoholic Fatty Liver Disease and Non‐Alcoholic Steatohepatitis in the Overweight and Obese Population: A Systematic Review and Meta‐Analysis,” Lancet Gastroenterology & Hepatology 8 (2023): 20–30, 10.1016/S2468-1253(22)00317-X. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous